A5030538256- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Drug Transport and Resistance Mechanisms
- Colorectal and Anal Carcinomas
- Cancer-related molecular mechanisms research
- Cancer therapeutics and mechanisms
- MicroRNA in disease regulation
- RNA Interference and Gene Delivery
- Pancreatic and Hepatic Oncology Research
- Nanoparticle-Based Drug Delivery
- Estrogen and related hormone effects
- Pharmacogenetics and Drug Metabolism
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- HIV/AIDS drug development and treatment
- Gastrointestinal Tumor Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Genetic Neurodegenerative Diseases
- Advanced biosensing and bioanalysis techniques
- Biochemical and Molecular Research
- Cancer Cells and Metastasis
- Gastric Cancer Management and Outcomes
Centro di Riferimento Oncologico
2012-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2021
Methodology and Quality of Life Unit in Oncology
2019
University of Trieste
2015
PharmacoGenetics (China)
2013
Among the several delivery materials available so far, polysaccharides represent very attractive molecules as they can undergo a wide range of chemical modifications, are biocompatible, biodegradable, and have low immunogenic properties. Thus, contribute to significantly overcome limitation in use many types drugs, including anti-cancer drugs. The conventional drugs is hampered by their high toxicity, mostly depending on indiscriminate targeting both cancer normal cells. Additionally, for...
Pre-therapeutic DPYD pharmacogenetic test to prevent fluoropyrimidines (FL)-related toxicities is not yet common practice in medical oncology. We aimed at investigating the clinical validity of genetic analysis a large series oncological patients. Six hundred three cancer patients, treated with FL, have been retrospectively tested for eight polymorphisms (DPYD-rs3918290, DPYD-rs55886062, DPYD-rs67376798, DPYD-rs2297595, DPYD-rs1801160, DPYD-rs1801158, DPYD-rs1801159, DPYD-rs17376848)...
Objective Membrane transporters are widely recognized as important determinants of drug disposition and response, generating increasing interest on the pharmacological implications their genetic variations. The aim this study was to elucidate predictive/prognostic role ATP-binding cassette (ABC) solute carrier (SLC) protein polymorphisms irinotecan (FOLFIRI regimen) outcome. Patients methods A total 250 White metastatic colorectal cancer patients homogenously treated with a first-line...
Lack of information on the clinical utility preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in practice. This study aimed to define association between variants and fluoropyrimidine‐related toxicity management costs. A cost analysis was conducted toxicities experienced by 550 patients with colorectal cancer treated fluoropyrimidine‐based chemotherapy. Genotyping for *2A , *13 c. 2846A>T ‐HapB3 UGT 1A1*28 done retrospectively did not affect...
Pharmacogenomics has largely been applied to the personalization of irinotecan-based treatment, focusing mainly on study genetic variants in adsorption, distribution, metabolism, and excretion (ADME) genes. The transcriptional control ADME gene expression is mediated by a set nuclear factors responding cancer-related inflammation, which could have pharmacological implications. aim present was uncover novel predictors neutropenia gastrointestinal toxicity risk among 246 haplotype-tagging...
Nuclear receptors act as mediators of cancer-related inflammation and gene expression. They have a regulatory effect on genes encoding proteins related to drug adsorption, distribution, metabolism, excretion. The aim the present study was highlight novel prognostic markers among polymorphisms in for nuclear receptor inflammation-related cytokines patients treated with FOLFIRI regimen. This included two independent cohorts comprising total 337 mCRC homogeneously first-line FOLFIRI. Genotyping...
In rectal cancer, a pathologic complete response (pCR) to pre-operative treatment is favourable prognostic marker, but reported in minority of the patients. We aimed at identifying microRNA-related host genetic polymorphisms predictive pCR. A panel 114 tagging was selected and analyzed on 265 locally advanced cancer patients treated with neoadjuvant chemo-radiotherapy. Patients were stratified two subgroups according radiotherapy dose (50.4Gy for 202 patients, 55.0Gy 78 patients)....
Background: Pathological complete response (pCR) to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is still ascribed a minority of patients. A pathway based-approach could highlight the predictive role germline single nucleotide polymorphisms (SNPs). The primary aim this study was define new biomarkers considering treatment specificities. Secondary determine potential independent from radiotherapy (RT) dosage and cotreatment with oxaliplatin. Methods: Thirty...
// Chiara Zanusso 1 , Roberto Bortolus 2 Eva Dreussi Jerry Polesel 3 Marcella Montico Erika Cecchin Sara Gagno Flavio Rizzolio Mauro Arcicasa Giacomo Novara 4 Giuseppe Toffoli Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, PN, Italy Department of Radiation Oncology, Epidemiology Biostatistics Surgery, Gastroenterology, University Padua, Correspondence to: Toffoli, email: gtoffoli@cro.it Keywords: prostate cancer, polymorphisms, biochemical recurrence, overall...
There are clinical challenges related to adjuvant treatment in colorectal cancer (CRC) and novel molecular markers needed for better risk stratification of patients. Our aim was integrate our previously reported clinical-genetic prognostic score with new immunogenetic 5-year disease-free survival (DFS) evaluate the recurrence before fluoropyrimidine (FL)-based therapy. The study population included a total 270 stage II-III CRC patients treated FL (FL+OXA, n=119) or without oxaliplatin (FL,...
Up to 30–50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization PCa patients’ treatment. aim this study is immunogenetic 10 year BCR (primary aim), overall survival (OS) and 5 (secondary aims). In mono-institutional retrospective study, 549 Caucasian (a discovery set n = 418; a replication 131) were affected by...
Identifying patients at risk of poor response to neoadjuvant chemoradiotherapy (nCRT) is an emerging clinical need in locally advanced rectal cancer (LARC). SMAD3 a key player the chemoradio-resistance phenotype and its expression both constitutive induced. The aim was investigate host (genetic polymorphisms) tumor profiling predict nCRT. In group 76 LARC patients, phosphorylated-SMAD3 assessed by immunohistochemistry preoperative tissue. expanded study (n = 378), set polymorphisms...
Abstract Host genetic variation in the immune factors has potential to highlight individual characteristics of tumor risk, prognosis, and response treatment. In locally advanced rectal cancer (LARC) no predictive prognostic are available select patients for multimodality treatment comprising neoadjuvant chemoradiation followed by radical surgery, possibly adjuvant chemotherapy. This work aimed at identifying immunogenetic markers significance LARC treated A panel 192 tagging polymorphisms...